Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Cost effectiveness of palivizumab in Spain: an analysis using observational data.

Nuijten MJ, Wittenberg W.

Eur J Health Econ. 2010 Feb;11(1):105-15. doi: 10.1007/s10198-009-0206-x. Epub 2009 Dec 5.

2.

Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children: a UK analysis.

Nuijten MJ, Wittenberg W, Lebmeier M.

Pharmacoeconomics. 2007;25(1):55-71.

PMID:
17192118
3.

Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.

Wang D, Cummins C, Bayliss S, Sandercock J, Burls A.

Health Technol Assess. 2008 Dec;12(36):iii, ix-x, 1-86. Review.

4.

[The efficiency (cost-effectiveness) of palivizumab as prophylaxis against respiratory syncytial virus infection in premature infants with a gestational age of 32-35 weeks in Spain].

Lázaro y de Mercado P, Figueras Aloy J, Doménech Martínez E, Echániz Urcelay I, Closa Monasterolo R, Wood Wood MA, Fitch Warner K.

An Pediatr (Barc). 2006 Oct;65(4):316-24. Spanish.

5.

The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .

Lanctôt KL, Masoud ST, Paes BA, Tarride JE, Chiu A, Hui C, Francis PL, Oh PI.

Curr Med Res Opin. 2008 Nov;24(11):3223-37. doi: 10.1185/03007990802484234 . Epub 2008 Oct 16.

PMID:
18928643
6.

Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.

Lofland JH, O'Connor JP, Chatterton ML, Moxey ED, Paddock LE, Nash DB, Desai SA.

Clin Ther. 2000 Nov;22(11):1357-69.

PMID:
11117660
7.

Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.

Roeckl-Wiedmann I, Liese JG, Grill E, Fischer B, Carr D, Belohradsky BH.

Eur J Pediatr. 2003 Apr;162(4):237-44. Epub 2003 Feb 6.

PMID:
12647196
9.

Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.

Resch B, Sommer C, Nuijten MJ, Seidinger S, Walter E, Schoellbauer V, Mueller WD.

Pediatr Infect Dis J. 2012 Jan;31(1):e1-8. doi: 10.1097/INF.0b013e318235455b.

PMID:
21960187
10.

Health economics and RSV.

Carbonell-Estrany X, Lázaro y de Mercado P.

Paediatr Respir Rev. 2009 Jun;10 Suppl 1:12-3. doi: 10.1016/S1526-0542(09)70006-5. Review.

PMID:
19651392
11.

Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden.

Neovius K, Buesch K, Sandström K, Neovius M.

Acta Paediatr. 2011 Oct;100(10):1306-14. doi: 10.1111/j.1651-2227.2011.02309.x. Epub 2011 May 13.

PMID:
21477089
12.

Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.

Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA.

Pediatrics. 1999 Sep;104(3 Pt 1):419-27.

PMID:
10469764
13.

Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.

Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, Stiles A.

Pediatrics. 2004 Dec;114(6):1612-9.

PMID:
15574623
14.

Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.

Hampp C, Kauf TL, Saidi AS, Winterstein AG.

Arch Pediatr Adolesc Med. 2011 Jun;165(6):498-505. doi: 10.1001/archpediatrics.2010.298. Epub 2011 Feb 7.

PMID:
21300647
15.

Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective.

Mahadevia PJ, Masaquel AS, Polak MJ, Weiner LB.

J Med Econ. 2012;15(5):987-96. doi: 10.3111/13696998.2012.690013. Epub 2012 May 10.

PMID:
22574798
16.

Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.

Elhassan NO, Sorbero ME, Hall CB, Stevens TP, Dick AW.

Arch Pediatr Adolesc Med. 2006 Oct;160(10):1070-6.

PMID:
17018467
17.

Cost-effectiveness of palivizumab against respiratory syncytial viral infection in high-risk children in Austria.

Resch B, Gusenleitner W, Nuijten MJ, Lebmeier M, Wittenberg W.

Clin Ther. 2008 Apr;30(4):749-60.

PMID:
18498923
18.

Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.

Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM.

Arch Pediatr Adolesc Med. 2000 Jan;154(1):55-61.

PMID:
10632251
19.

Economic analysis of palivizumab in infants with congenital heart disease.

Yount LE, Mahle WT.

Pediatrics. 2004 Dec;114(6):1606-11.

PMID:
15574622
20.

Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.

Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J; IRIS Study Group.

Pediatr Infect Dis J. 2003 Sep;22(9):823-7.

PMID:
14506376
Items per page

Supplemental Content

Write to the Help Desk